There were 1,737 press releases posted in the last 24 hours and 405,182 in the last 365 days.

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.

Conference Call Information:

Date:    Thursday, February 25, 2021
Time:   8:30 am Eastern Time
Domestic Dial-in:     877-423-9813
International Dial-in:       201-689-8573
Conference ID:   13716171
Webcast:       http://public.viavid.com/index.php?id=143423

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:

Will Brown Stacey Jurchison
Chief Financial Officer                                    Sr. Dir, Investor Relations
Phone: 240-654-1450      Phone : 410-474-8200  
wbrown@altimmune.com      sjurchison@altimmune.com 

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.